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BACKGROUND AND PURPOSE: Serial in vivo imaging of atherosclerosis is important for understanding
plaque progression and is potentially useful in predicting cardiovascular events and monitoring treat-
ment efficacy. This prospective study aims to quantify temporal changes in carotid atherosclerotic
plaque volume and plaque composition using MDCTA.
MATERIALS AND METHODS: In 109 patients with TIA or ischemic stroke, serial MDCTA of the carotid
arteries was performed after 5.3 0.7 years. The carotid bifurcation was semiautomatically registered
for paired baseline follow-up datasets. Outer vessel wall and lumen boundaries were defined using
semiautomated segmentation tools. Plaque component volumes were measured using HU thresh-
olds. Annual changes in plaque volume and plaque component proportions were calculated.
RESULTS: One-hundred-ninety-three carotid arteries were analyzed. Plaque volume decreased in 31%
and increased in 69% of vessels (range5.6–10.1%/year). Overall, plaque volume increased 1.2% per
year (95% CI, 0.8–1.6, P  .001). Plaque composition changed significantly from BL (fibrous 66.4%,
lipid 28.8%, calcifications 4.8%): fibrous tissue decreased by 1.5%, lipid decreased by 1.8%, and
calcification increased by 3.3% (P  .001). Intraobserver reproducibility of all volume and proportion
measurements was good (ICC 0.78–1.00) and interobserver reproducibility was moderate (ICC
0.76–0.99).
CONCLUSIONS: Changes in carotid plaque burden and plaque composition can be quantified by using
serial MDCTA. Plaque burden development is a heterogeneous and slow process.
ABBREVIATIONS: BL  baseline; CCA  common carotid artery; CLL  central lumen line; CoV 
coefficient of variation; ECA external carotid artery; FU follow-up; HU Hounsfield unit; ICC
intraclass correlation coefficient; IQR  interquartile range; MDCTA  multidetector CT angiogra-
phy
Atherosclerosis is a slowly progressing disease, sub-clinical for decades before suddenly causing clinical
manifestations such as coronary artery disease, ischemic
cerebrovascular disease, and peripheral artery disease. In-
creased atherosclerotic burden first causes outward remod-
eling of the artery, with compensatory expansion of the
outer vessel wall boundary without narrowing of the lu-
men.1 In later stages of plaque progression, the compensa-
tory mechanism of outward remodeling no longer suffices,
and the vessel lumen becomes compromised, eventually
causing stenosis or occlusion. Besides the hemodynamic
effects on blood flow and blood pressure, atherosclerotic
disease is thought to induce ischemic events by plaque rup-
ture, causing thrombosis and obstruction, or thromboem-
bolization, into distal arteries. Increased lipid content, large
lipid-rich necrotic cores, intraplaque hemorrhage, inflam-
mation, and thin fibrous caps are the hallmarks of plaques
vulnerable to rupture.2,3
Knowledge of atherosclerotic plaque development has pre-
dominantly been derived from animal and histopathologic
studies.4 Still, little is known about progression of atheroscle-
rosis in humans. Serial in vivo imaging of both vessel lumen
and plaque is important for understanding the development
of atherosclerotic plaque and its progression from subclinical
lesions into rupture-prone plaques. Accurate monitoring of
changes in atherosclerotic plaque burden and composition
can potentially be used in risk prediction and in assessing ef-
ficacy of pharmaceutical treatment.
MDCTA has been validated for imaging atherosclerotic
plaque in the carotid arteries in vivo.5,6 Plaque volume and
several plaque components, such as calcifications, lipids, and
fibrous tissues, can be accurately quantified.5,7MDCTA there-
fore provides a minimally invasive tool to investigate carotid
plaque progression in humans.
In this prospective study, serial CT angiography of the ca-
rotid arteries was performed in patients with TIA or ischemic
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stroke, and changes in plaque burden and plaque composition
were quantified using a semiautomated custom-made plaque
segmentation tool.
Materials and Methods
Study Population
Patients were recruited from a cohort of 914 consecutive patients with
TIA or ischemic stroke who had undergone a standard clinical work-
up, including multidetector CT angiography of the carotid arteries.8
All patients with atherosclerotic plaque (ie, thickening and/or calcifi-
cation of the vessel wall) in 1 or both carotid arteries were invited to
participate in this serial imaging study. Exclusion criteria included no
atherosclerotic plaque(s) present at the level of the carotid bifurca-
tion, bilateral occlusion and/or treatment of the carotid arteries, no
informed consent, renal insufficiency or hyperthyroidism, and bad
image quality of the baseline scan. Blood samples to determine renal
function were taken, if necessary. The study was approved by the
Local Institutional Ethics Review Board. All patients gave written in-
formed consent.
The serial MDCTA datasets of the first 113 patients included in
this study were used for analysis. The MDCTA data from 4 patients
were excluded because of motion artifacts or low lumen contrast at-
tenuation. In addition, 6 arteries were excluded from the analysis
because of occlusion on baseline and/or follow-up scan; 14 because of
local treatment with carotid endarterectomy or stent placement; and
5 because of (focal) poor image quality (perivenous artifacts or streak
artifacts due to dental material) impeding correct plaque segmenta-
tion. In total, 193 carotid arteries from 109 patients were included in
this study.
Clinical Data
As a part of routine clinical work-up, all patients underwent a detailed
health questionnaire, a physical examination, laboratory measure-
ments, a CT scan of the brain, and multidetector CT angiography of
the carotid arteries. Informationwas collected on age, sex,medication
use, hypertension, hypercholesterolemia, diabetes mellitus, smoking,
and history of cerebrovascular or cardiovascular disease, as previously
described.8During the visit for the follow-upMDCTA scan, a detailed
health questionnaire was taken.
Multidetector CT Angiography Protocol
BL scans were performed on a 16- or 64-section multidetector CT
scanner (Sensation 16/64; SiemensMedical Solutions, Erlangen, Ger-
many), with a standardized optimized contrast-enhanced protocol
(collimation 16 0.75 mm [n 106] or 2 32 0.6 mm [n 3],
pitch 1) and a scan range ranging from the ascending aorta to the
intracranial arteries. The follow-up scans were performed on a 128-
section multidetector CT scanner (Somatom Definition; Siemens
Medical Solutions), with a comparable protocol (collimation 2 
64 0.6 mm, pitch 0.7) and a scan range of 6 cm around the carotid
bifurcation. Eighty mL of contrast material was used, with a saline
bolus chaser of 40 mL and real-time bolus tracking in the ascending
aorta, using a threshold of 120 HU.
Image reconstructions for all scans were made with a FOV of 120
mm,matrix size 512 512, section thickness of 1.0mm, increment of
0.6 mm, and with both a smooth (B30/B31) and an intermediate
(B46) filter kernel, ofwhich the last one has beendemonstrated to give
the best soft tissue contrast.9 We performed a point-spread-function
analysis using a standard thinwire phantom10 to test for differences in
in-plane resolution between similar kernels on different scanners, but
we did not find any differences.
Registration of Baseline and Follow-Up Scan
To accurately compare the baseline plaque measurements with those
at follow-upwithin each patient, the carotid bifurcation onboth scans
were registered using a custom-made semiautomated registration
tool (Fig 1). First lumen segmentation was generated by a level-set-
based method, initialized with 3 seed points in the CCA, ICA, and
ECA.11 From this lumen segmentation, a CLL was extracted. Then 3
new observer-defined initialization points in, respectively, the CCA,
the ICA, and the ECA on the follow-upMDCTAmarked the range to
be segmented for plaque analysis. Using the bifurcation point (the
level at which the CCA lumen separates into the 2 separate lumens of
ICA and ECA) as a landmark, the absolute distances along the CLL
from this point to the initialization points were calculated and copied
to theCLLs of the baselineMDCTA todefine the corresponding vessel
part of interest on the baseline scan (on axial sections). In this way,
adjustments were made for possible differences between the baseline
and the follow-up scan in the curvature of the carotid arteries due to
elongation or head position. Scan data reconstructed with a B46 ker-
nel were used.
Plaque Analysis
Volume measurements of lumen, vessel wall, and vessel wall compo-
nents (further defined as plaque and plaque components, respec-
tively) were derived using a custom-made semiautomated plaque
analysismethod. The lumen segmentation used in registering the ves-
sel range of interest between baseline and follow-up scan was also
used here. The outer vessel wall was segmented based on a method
using a gentle boost classifier, which had been trained by manually
annotated data.12,13 The lumen segmentations and outer vessel wall
segmentations were checked and adjustedmanually, where appropri-
ate. The plaque was derived by subtracting the lumen segmentation
from the outer vessel wall segmentation.
After segmenting the carotid artery outer vessel wall and lumen,
plaque components were differentiated based on HU thresholds. The
cut-off value between calcifications and fibrous tissue was set at 130
HU, as used for calcium scoring. The threshold used to differentiate
lipid from fibrous tissue was 60 HU, a setting that was previously
validatedwith histology.5 The volumes of the plaque and plaque com-
ponents were calculated as the product of the number of pixels in the
segmented areas, the pixel size, and the section increment. The pro-
portion of plaque components was calculated as the ratio of the vol-
ume of the component to the total plaque volume, multiplied by 100.
Figure 2 shows an example of axial sections through a carotid bifur-
cation at baseline and follow-up and their corresponding plaque
segmentations.
Stenosis measurements were performed according to the
NASCET criteria. Using 3D software, multiplanar reformats were
made and the smallest diameter was measured on axial images per-
pendicular to the vessel axis.
Reproducibility of Semiautomated Plaque Measurements
Although the procedure was automated for a large part, there were
some observer interventions: clicking initialization points for lu-
men segmentation, clicking initialization points for defining the
range for plaque segmentation, and manually adjusting the lumen
and outer vessel wall segmentations, if necessary. To assess the
intraobserver and interobserver variability of the complete
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method, a subset of 30 carotid arteries was analyzed 2 times by the
same observer, with a delay of 3 months, and once by a second
observer. This subset was randomly taken from the group of pa-
tients without a treated artery, an occluded carotid artery, or poor
Fig 2. Semiautomatically generated plaque segmentations on matched BL and FU axial MDCTA images just above the level of the carotid bifurcation. The time interval between the scans
is 5.8 years; a slight plaque progression with an increase in calcifications is visible. Red  lumen; green  fibrous tissue; yellow  lipid; white  calcification.
Fig 1. Explanation of the method of semiautomated registration of vessel wall range of interest. 3D reconstructions of the lumen segmentations of a carotid bifurcation at FU (A) and at
BL (B). Lumen segmentation is semiautomatically generated after clicking 3 initialization points in the CCA, the ICA, and the ECA, respectively (red dots), separately in both FU and BL
datasets. From this lumen segmentation, CLLs are extracted (orange line). On the FU CTA, the vessel range containing atherosclerotic plaque is defined by clicking another set of initialization
points (blue dots). The absolute distances along the CLL between the 3 blue points are measured and copied to the CLL of the BL CTA (yellow line), which define the range on axial images
to be analyzed by the automated plaque segmentation tool (green dots).
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image quality. The intraobserver and interobserver variability are
presented as ICC and CoV.
Data Analysis
Plaque volume and plaque component volumes and proportions
were measured on both sides in each individual at baseline and fol-
low-up within the registered range of interest. Within each carotid
artery, the changes over time of the different plaque measures were
derived.
The data are presented asmean SD. Total vessel, lumen, plaque,
and plaque components are presented as absolute volumes (in mm3)
on baseline and follow-up. Plaque components are also expressed as
proportions. A paired t test was used for the analysis of absolute pro-
gression from baseline to follow-up.
Temporal changes are expressed as absolute annual change in vol-
ume or proportion ([change in volume or proportion/FU time in
months]*12), and as a percentage (“relative”) annual volume change
frombaseline (absolute annual change in volume/BL volume). A one-
sample t test was used for comparison of “annual change” to 0.
Correlations between percentage annual growth of plaque volume
and BL plaque characteristics were described by Pearson correlation
coefficient. Correlations between absolute change in plaque compo-
nent proportion and baseline characteristics were described by Pear-
son correlation, or by Spearman correlation coefficient, when appro-
priate. To avoid an induced (spurious) correlation between absolute
or percentage annual change in a plaque feature and its baseline value,
the mean of the measure at baseline and follow-up was used.14
Results
Baseline Characteristics
The clinical information on the 109 included patients is sum-
marized in Table 1. The median time delay between the event
and the baseline scan was 11 (IQR 5–21) days and the mean
interval between the scans was 5.3  0.7 years. In just a few
cases, the degree of stenosis of the artery changed into a higher
degree over time (Table 2). Baseline plaque volume was
1100  464 mm3. The contributions of the different compo-
nents at baseline were 66.4  7.8%, 28.8  5.4%, and 4.8 
6.9% for fibrous tissue, lipid, and calcification, respectively
(Table 3). Calcifications were present in 132 carotid arteries
(68.4%).
Atherosclerotic Plaque Growth
Of 193 arteries, 60 (31%) showed decrease in plaque volume
(mean difference between BL and FU 119 mm3, 95% CI,
151 – 86 mm3), while in 133 (69%), plaque volume in-
creased (mean difference 127 mm3, 95% CI, 109–146 mm3).
The mean volumes and plaque component proportions at
baseline and follow-up for the entire group are summarized in
Table 3. There was a significant overall growth in plaque vol-
ume of 51mm3 (95%CI, 28–74mm3). Lumen and total vessel
volume also increased significantly over time. Whereas the
absolute values of fibrous tissue and lipid did not change sig-
nificantly, their relative contribution to the plaque volume
decreased (1.5% and 1.8%, respectively, P  .001). The
proportion of calcification within the plaque increased by
3.3% (P .001).
Annualized Changes in Plaque Measures
Overall, the percentage annual growth of total vessel volume,
lumen volume, and plaque volume were 0.63% per year (95%
CI, 0.44–0.83), 0.55% per year (95% CI, 0.25–0.85), and
1.16% per year (95% CI, 0.76–1.55), respectively. Absolute
annual changes in the proportions of the components were a
decrease of 0.26%per year for fibrous tissue (95%CI,0.41%
– 0.10%), a decrease of 0.37% per year for lipid (95% CI,
0.51% – 0.24%), and an increase of 0.64% per year for
calcifications (95% CI, 0.54–0.74; all Ps .001).
Relation Between Plaque Changes and BL Plaque
Characteristics
Regression analysis showed no significant correlation between
percentage annual plaque growth and plaque volume (P 
.196). No correlations were found between percentage annual
plaque growth and plaque component proportions at
baseline.
The change in calcium proportion was significantly corre-
lated with baseline plaque volume (rs  0.45, P  .001) and
calcium proportion (rs 0.68, P .001). Annual increase in
calcium proportion was larger in arteries with baseline plaque
volume larger than 975 mm3 (ie, larger than the median of
baseline plaque volume, n 96) compared with arteries with
a baseline plaque volume smaller than 975 mm3 (n  97;
0.88% versus 0.39% per year; P  .001). Annual increase in
calcium proportion was larger in plaques with a high baseline
calcium proportion (3.9%, median of average calcium pro-
portion on baseline and follow-up, n  96) compared with
Table 1: Baseline patient characteristics
Baseline Patient Characteristics
(n  109) Value
Age (years; mean  SD) 62.8 8.5
Male sex (n %) 70 (64%)
Hypertension (n %) 76 (70%)
Hypercholesterolemia (n %) 90 (83%)
Diabetes mellitus (n %) 11 (10%)
Smoking (current or past; n %) 87 (80%)
Previous cardiovascular disease (n %) 19 (17%)
Previous cerebrovascular disease (n %) 25 (23)%
Symptoms (n %)
Amaurosis fugax 18 (17%)
Transient ischemic attack 50 (46%)
Minor stroke 41 (38%)
Use of secondary preventive medication during FU (n %)
Cholesterol lowering 98 (90%)
Antihypertensive 80 (73%)
Antidiabetic 17 (16%)
Time delay BL–FU MDCTA (years; mean  SD) 5.3 0.7
Table 2: Stenosis measurements at baseline and at follow-up as
assessed according to the NASCET criteria
Baseline
Follow-Up
0–29% 30–49% 50–69% 70–99% Total
0–29% 160 7 0 1 168
30–49% 1 13 4 0 18
50–69% 0 0 5 1 6
70–99% 0 0 0 1 1
Total 161 20 9 3 193
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those with a low baseline calcium proportion (3.9%, n 97;
1.00% versus 0.26% per year; P .001).
Reproducibility of the Method
The ICC for all volume and proportion measures varied be-
tween 0.92 and 1.00 for intraobserver reproducibility, except
for lipid proportion and lipid volume, which were 0.78 and
0.86, respectively. The ICC for interobserver reproducibility
varied between 0.76 and 0.99. The CoVs were good for intra-
observer variability, varying between 4.6% and 11.4%, except
for lipid volume, which was 19.0%. For interobserver variabil-
ity, the CoVs were moderate and varied between 4.5% and
22.0% (Table 4).
Discussion
To our knowledge, this is the first in vivo serial CTA study to
investigate atherosclerotic carotid plaque progression in hu-
mans. This study demonstrates that multidetector CT angiog-
raphy can be used to quantify atherosclerotic plaquemeasures
in vivo and track changes over time in large study populations.
In 193 carotid arteries, themean percentage annual growth
in plaque volume was 1.2% per year, with a wide range from
5.6% to 10.1% per year. MR imaging has been proven as a
reproducible method for plaque quantification,15-18 and sev-
eral serial MR imaging studies have been performed for track-
ing changes in carotid atherosclerosis. In a prospective MR
imaging study, Saam et al described a yearly increase of 2.2%
in wall area in50% stenosed carotid arteries.19 Boussel et al
found an annual rate of progression of carotid vessel wall vol-
ume of 2.3% per year in arteries with 50% stenosis.20 In
these studies, however, the included arteries had more severe
stenosis compared with the arteries included in our study. In
another study, a carotid total wall volume increase of 1.2%and
1.8% was found after 16 and 24 months, respectively, in pa-
tients whowere on statin treatment.15 These results were com-
parable with ours. MR imaging studies often use different
measures (area or eccentric wall volume) for assessing plaque
growth, which leads to another difficulty in comparing our
results to those from previous serial in vivo studies. Neverthe-
less, the growth rate of carotid plaque turns out to be remark-
ably small and highly variable, a comparable finding across
studies. Statin treatment has been shown to induce reduced
progression or even regression of plaque burden.19-25 Approx-
imately 90% of patients in our study were using statins during
the follow-up period. Thirty-one percent of our patients
showed plaque regression, a number similar to that found in
other plaque progression studies in which most patients were
on statin therapy.19,20 Statin treatment might therefore be a
reason for the small mean growth in plaque volume.
We did not find any local baseline plaque characteristics
significantly associated with plaque volume growth. In con-
trast, Saam et al found that a normalized wall index0.64, as
a measure of large plaque burden, was associated with a re-
duced rate of progression in mean wall area.19
In this study, we found a change in plaque composition
over time: calcification proportion increased, which coincides
with a decrease in fibrous and lipid proportion. Larger plaques
had a faster increase in calcium proportion compared with
smaller plaques, and the more calcified plaques showed a sig-
nificantly larger annual increase in calcium proportion than
the less calcified plaques. Calcified carotid plaques are thought
to be more stable compared with noncalcified plaques.26-28
The results of this longitudinal study therefore suggest that
when plaques progress, they finally get a more stable profile.
This might also be an effect of the secondary preventive med-
ication that is used bymost patients. A few studies reported on
the change in composition toward a more stable plaque phe-
notype in statin-treated patients, by demonstrating a decrease
Table 3: Baseline and follow-up measurements of plaque volume and plaque components
BL ( SD) FU ( SD) Mean Paired Difference (95% CI) P valuea
Vessel volume (mm3) 2575.4 993.6 2657.6 1022.5 82.2 (55.9–108.5) 0.001
Lumen volume (mm3) 1475.2 620.2 1506.5 621.9 31.3 (9.8–52.8) 0.005
Plaque volume (mm3) 1100.2 464.0 1151.1 466.7 50.9 (28.1–73.7) 0.001
Fibrous volume (mm3) 712.2 260.7 726.4 262.9 14.2 (2.4–30.8) 0.094
Lipid volume (mm3) 318.3 154.1 309.0 134.1 9.3 (21.1–2.6) 0.124
Calcium volume (mm3) 69.7 124.6 115.7 152.9 46.0 (37.6–54.4) 0.001
Fibrous proportion (%) 66.4 7.8 64.9 9.4 1.5 (2.3–0.7) 0.001
Lipid proportion (%) 28.8 5.4 27.0 5.9 1.8 (2.5–1.1) 0.001
Calcium proportion (%) 4.8 6.9 8.1 8.6 3.3 (2.8–3.9) 0.001
a As evaluated with a paired t test
Table 4: Intraobserver and interobserver variability (n  30 carotid arteries) of the semiautomatic segmentation method
Intraobserver Interobserver
Mean SD Diff Obs ICC CoV (%) Mean SD Diff Obs ICC CoV (%)
Vessel volume (mm3) 2606 830 50 244 0.96 9.4 2743 848 323 407 0.84 14.9
Lumen volume (mm3) 1527 535 5 152 0.96 10.0 1630 567 201 266 0.85 16.3
Plaque volume (mm3) 1079 350 55 120 0.93 11.1 1112 334 123 164 0.84 14.7
Fibrous volume (mm3) 649 178 33 64 0.92 9.9 675 185 86 115 0.76 17.0
Lipid volume (mm3) 316 114 19 60 0.86 19.0 326 110 39 70 0.78 21.5
Calcium volume (mm3) 114 120 3 7 1.00 6.5 112 115 2 13 0.99 12.0
Fibrous proportion (%) 61 8 0.5 2.8 0.94 4.6 62 8 0.8 2.7 0.94 4.5
Lipid proportion (%) 29 4 0.1 3.0 0.78 10.4 29 5 0.4 3.0 0.80 10.2
Calcium proportion (%) 9 8 0.6 1.1 0.99 11.4 9 8 1.2 2.0 0.96 22.0
Note:—Diff Obs indicates difference between observers.
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in lipid content29,30 and a trend towardmore calcium.30 How-
ever, these results should be confirmed in larger randomized
trials investigating the influence of statin use on plaque
composition.
Glagov et al were the first to report on outward vascular
remodeling, showing an increase in total vessel area as an
adaptive mechanism to preserve lumen area in response to
increasing atherosclerotic disease burden. Luminal narrowing
did not occur until the atherosclerotic lesion occupied40%
of the internal elastic lamina area.1 In our study, including
only arteries with mild atherosclerotic disease, we also found
an overall increase in total vessel volume following an increase
in plaque volume. The changes in plaque burden over time
appeared to be too small for lumen to become compromised.
This might also explain why a change in degree of stenosis was
demonstrated in only a minority of vessels.
One of the major challenges in serial imaging studies on
atherosclerotic plaques is the reproducibility of quantitative
measures. In our study, we used volumemeasurements, which
have been shown to be more precise than area measure-
ments.17 Several studies have investigated factors influencing
measurement errors. Differences in head positioning is one
such factor that can cause the 3D position of the carotid bifur-
cation to change significantly,31 thereby causing difficulties in
matching corresponding axial cross-sectional images across
different time points. So far, registration of carotid arteries has
been performedmanually using landmarks such as the carotid
bifurcation point. In this study, we matched the range of in-
terest in the carotid artery semiautomatically using the dis-
tance along the central vessel lumen line, accounting for pos-
sible variation in carotid position over time. Further
improvement would be achieved if analyses could be per-
formed in sections perpendicular to the central line of the
artery.
Semiautomated measurement of plaque volumes might
improve reproducibility. When we compare our results, using
a semiautomated plaque segmentation method, with the in-
terobserver reproducibility found in a previous study in which
plaque segmentationwas donemanually, interobserver repro-
ducibility improved; CoV for plaque volume was 15% com-
pared with 23%–34% found with the manual segmentation
method. De Weert et al demonstrated that their moderate in-
terobserver reproducibility was partly due to the difficulty of
defining the exact plaque range; consensus about the segmen-
tation range improved the reproducibility.7 Therefore, taking
a fixed range around the bifurcation to be segmented may
further improve interobserver and intraobserver reproduc-
ibility of the semiautomatedmethod.Nevertheless, the annual
changes in plaquemeasures are relatively small comparedwith
the current intraobserver variability and, though significant
for the whole group, these would not be meaningful for the
individual patient.
Our study has some limitations. First, in contrast to MR
imaging, MDCTA is not capable of visualizing fibrous cap
rupture or intraplaque hemorrhage. Both plaque features are
highly associated with plaque rupture and ischemic
events.32-36 Intraplaque hemorrhage has also been associated
with an accelerated plaque growth.35We have not been able to
analyze the influence of this important plaque characteristic
on plaque development. On the other hand, HU-based differ-
entiation of plaque components enable serial and automated
plaque composition measurements in MDCTA data. Calcifi-
cations and changes herein can be accurately measured using
MDCTA.ComparedwithMR imaging datasets, inwhichmul-
tiple sequences are necessary to obtain all plaque information,
MDCTA data are more robust and allow minimal observer
intervention in the steps toward registration and lumen and
vessel wall segmentation. High availability and a quick proce-
dure are advantages of MDCTA that make it a promising tool
for serial plaque imaging. With the present CT scanners and
precautionary measures, the risks of the potentially harmful
radiation exposure and intravenous contrast material can be
reduced to a minimum.
Second, we reported on plaque volume, whereas, with
MDCTA, we are not able to distinguish atherosclerotic plaque
itself from the underlying media. In serial studies, this is of
minor importance, because the outcome measure of inter-
est—the difference over time—will merely consist of changes
in the plaque itself as the range of interest is registered across
BL and FU scans.
No evidence exists for a linear pattern of atherosclerotic
plaque growth, and the annual change rate is therefore an ar-
tificialmeasure. However, this study corrects for differences in
follow-up time and creates a measure that can be compared
across groups and studies.
Further, this study was performed in patients with TIA and
stroke who were all on secondary preventive medication.
Given the known effects of statins on plaque progression, our
results cannot be extrapolated to the asymptomatic
population.
Conclusions
The present study shows that MDCTA enables quantification
of carotid plaque progression and plaque composition
changes in vivo in large patient groups. Carotid atheroscle-
rotic plaque progression seems to be a slow and heterogeneous
process. It is unknown yet whether monitoring plaque pro-
gression might have future clinical value in risk prediction.
Further research should therefore focus on the associations
between temporal plaque changes found with serial imaging
and (recurrent) ischemic cerebrovascular events.
Disclosures: Marjon van Gils—RELATED: Support for Travel to Meetings for the Study or
Other Purposes: Netherlands Hearth Foundation. Wiro Niessen—RELATED: Grant: Dutch
Science Foundation; UNRELATED: Grants/Grants Pending: Dutch Science Foundation. Aad
van der Lugt—UNRELATED: Payment for Lectures (including service on speakers bureaus):
E Healthcare.* (*Money paid to institution.)
References
1. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of hu-
man atherosclerotic coronary arteries. N Engl J Med 1987;316:1371–75
2. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable
patient: a call for newdefinitions and risk assessment strategies: Part I.Circu-
lation 2003;108:1664–72
3. Underhill HR, YuanC, YarnykhVL, et al.Predictors of surface disruptionwith
MR imaging in asymptomatic carotid artery stenosis. AJNR Am J Neuroradiol
2010;31:487–93
4. Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque.
Arterioscler Thromb Vasc Biol 2010;30:1282–92
5. deWeert TT,OuhlousM,Meijering E, et al. In vivo characterization and quan-
tification of atherosclerotic carotid plaque components with multidetector
computed tomography andhistopathological correlation.Arterioscler Thromb
Vasc Biol 2006;26:2366–72
1272 van Gils  AJNR 33  August 2012  www.ajnr.org
6. Wintermark M, Jawadi SS, Rapp JH, et al. High-resolution CT imaging of
carotid artery atherosclerotic plaques.AJNRAmJNeuroradiol 2008;29:875–82
7. de Weert TT, de Monye C, Meijering E, et al. Assessment of atherosclerotic
carotid plaque volume with multidetector computed tomography angiogra-
phy. Int J Cardiovasc Imaging 2008;24:751–59
8. Homburg PJ, Rozie S, van Gils MJ, et al. Atherosclerotic plaque ulceration in
the symptomatic internal carotid artery is associated with nonlacunar isch-
emic stroke. Stroke 2010;41:1151–56
9. de Weert TT, Ouhlous M, Zondervan PE, et al. In vitro characterization of
atherosclerotic carotidplaquewithmultidetector computed tomographyand
histopathological correlation. Eur Radiol 2005;15:1906–14
10. Nickoloff EL. Measurement of the PSF for a CT scanner: appropriate wire
diameter and pixel size. Phys Med Biol 1988;33:149–55
11. ManniesingR, SchaapM,Rozie S, et al.RobustCTA lumen segmentationof the
atherosclerotic carotid artery bifurcation in a large patient population.Med
Image Anal 2010;14:759–69
12. Vukadinovic D, Rozie S, van Gils M, et al. Automated versus manual segmen-
tation of atherosclerotic carotid plaque volume and components in CTA: as-
sociations with cardiovascular risk factors. Int J Cardiovasc Imaging 2012;28:
877–87
13. Vukadinovic D, vanWalsum T,Manniesing R, et al. Segmentation of the outer
vessel wall of the common carotid artery in CTA. IEEE Trans Med Imaging
2010;29:65–76
14. Tu YK, Baelum V, Gilthorpe MS. The problem of analysing the relationship
between change and initial value in oral health research. Eur J Oral Sci
2005;113:271–78
15. Adams GJ, Greene J, Vick GW 3rd, et al. Tracking regression and progression
of atherosclerosis in human carotid arteries using high-resolution magnetic
resonance imaging.Magn Reson Imaging 2004;22:1249–58
16. Kang X, Polissar NL, Han C, et al. Analysis of the measurement precision of
arterial lumen and wall areas using high-resolution MRI. Magn Reson Med
2000;44:968–72
17. Saam T, Kerwin WS, Chu B, et al. Sample size calculation for clinical trials
usingmagnetic resonance imaging for the quantitative assessment of carotid
atherosclerosis. J Cardiovasc Magn Reson 2005;7:799–808
18. SaamT,HatsukamiTS, YarnykhVL, et al.Reader andplatform reproducibility
for quantitative assessment of carotid atherosclerotic plaque using 1.5T Sie-
mens, Philips, and General Electric scanners. J Magn Reson Imaging 2007;26:
344–52
19. Saam T, Yuan C, Chu B, et al. Predictors of carotid atherosclerotic plaque
progression as measured by noninvasive magnetic resonance imaging. Ath-
erosclerosis 2007;194:e34–42
20. Boussel L, Arora S, Rapp J, et al.Atherosclerotic plaque progression in carotid
arteries: monitoring with high-spatial-resolution MR imaging–multicenter
trial. Radiology 2009;252:789–96
21. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on
human atherosclerotic lesions: a longitudinal study by high-resolution, non-
invasive magnetic resonance imaging. Circulation 2001;104:249–52
22. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces re-
gression of human atherosclerotic lesions: two years’ follow-up by high-res-
olution noninvasive magnetic resonance imaging. Circulation 2002;106:
2884–87
23. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy
with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by
noninvasive MRI. Eur J Cardiovasc Prev Rehabil 2009;16:222–28
24. Nissen SE,Nicholls SJ, Sipahi I, et al.Effect of veryhigh-intensity statin therapy
on regression of coronary atherosclerosis: the ASTEROID trial. JAMA
2006;295:1556–65
25. Underhill HR, Yuan C, Yarnykh VL, et al. Arterial remodeling in [corrected]
subclinical carotid artery disease. JACC Cardiovasc Imaging 2009;2:1381–89
26. Kwee RM. Systematic review on the association between calcification in ca-
rotid plaques and clinical ischemic symptoms. J Vasc Surg 2010;51:1015–25
27. Nandalur KR, Hardie AD, Raghavan P, et al.Composition of the stable carotid
plaque: insights from amultidetector computed tomography study of plaque
volume. Stroke 2007;38:935–40
28. Shaalan WE, Cheng H, Gewertz B, et al.Degree of carotid plaque calcification
in relation to symptomatic outcome and plaque inflammation. J Vasc Surg
2004;40:262–69
29. UnderhillHR,YuanC,ZhaoXQ, et al.Effect of rosuvastatin therapyon carotid
plaque morphology and composition in moderately hypercholesterolemic
patients: a high-resolution magnetic resonance imaging trial. Am Heart J
2008;155:584 e581–88
30. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-
lowering therapy on the characteristics of carotid atherosclerotic plaques in
vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001;21:
1623–29
31. Aristokleous N, Seimenis I, Papaharilaou Y, et al. Effect of posture change on
the geometric features of the healthy carotid bifurcation. IEEE Trans Inf Tech-
nol Biomed 2011;15:148–54
32. Altaf N, MacSweeney ST, Gladman J, et al. Carotid intraplaque hemorrhage
predicts recurrent symptoms in patients with high-grade carotid stenosis.
Stroke 2007;38:1633–35
33. Hatsukami TS, Ross R, PolissarNL, et al.Visualization of fibrous cap thickness
and rupture in human atherosclerotic carotid plaque in vivo with high-reso-
lution magnetic resonance imaging. Circulation 2000;102:959–64
34. YuanC, Zhang SX, PolissarNL, et al. Identification of fibrous cap rupturewith
magnetic resonance imaging is highly associated with recent transient isch-
emic attack or stroke. Circulation 2002;105:181–85
35. Takaya N, Yuan C, Chu B, et al. Presence of intraplaque hemorrhage stimu-
lates progression of carotid atherosclerotic plaques: a high-resolution mag-
netic resonance imaging study. Circulation 2005;111:2768–75
36. TakayaN, YuanC, Chu B, et al.Association between carotid plaque character-
istics and subsequent ischemic cerebrovascular events: a prospective assess-
ment with MRI–initial results. Stroke 2006;37:818–23
AJNR Am J Neuroradiol 33:1267–73  August 2012  www.ajnr.org 1273
